Thrombomodulin in sepsis

Minerva Anestesiologica

Volumn 79, Issue 3, 2013, Pages 294-298

  Levi, M ^a   Van Der Poll, T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Activated protein C resistance; Blood coagulation; Inflammation; Sepsis; Thrombomodulin

Indexed keywords

ACTIVATED PROTEIN C; HEPARIN; INTERLEUKIN 1; PLACEBO; PROTEIN S; RECOMBINANT THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA;

ADHESION; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DOWN REGULATION; DRUG CLEARANCE; DRUG EFFICACY; FOLLOW UP; HUMAN; IMMUNOMODULATION; KIDNEY DYSFUNCTION; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NOTE; PATHOGENESIS; PROTEIN EXPRESSION; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TREATMENT DURATION;

DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; INFECTION; MULTIPLE ORGAN FAILURE; PROTEIN C; SEPSIS; THROMBOMODULIN;

EID: 84878206958     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (29)

1. Anas A, Wiersinga WJ, de Vos AF, van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010;68:157-62.
2. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92. (Pubitemid 29384168)
3. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2010;30:10-6.
4. Lowenberg EC, Meijers JC, Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010;68:242-51.
5. Ratnoff OD, Nebehay WG. Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome. Ann Intern Med 1962;56:627.
6. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010;38:S26-S34.
7. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987;235:1348-52. (Pubitemid 17041653)
8. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996;271:16603-8. (Pubitemid 26239017)
9. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20.
10. Brandrzaeg P, Sandset PM, Joo GB, Ovstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989;55:459-70. (Pubitemid 19215683)
11. Levi M, Dorffler-Melly J, Reitsma PH, Buller HR, Florquin S, van der Poll T et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood 2003;101:4823-7. (Pubitemid 36857741)
12. Garcia de Frutos P, Alim RI, Hardig Y, Zoller B, Dahlback B. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994;84:815-22.
13. Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78:357-63.
14. Taylor FBJ, Dahlback B, Chang AC, Lockhart MS, Hatanaka K, Peer G et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995;86:2642-52.
15. Schouten M, de Boer JD, van't Veer C, Roelofs JJ, Meijers JC, Levi M et al. The lectin-like domain of thrombomodulin hampers host defense in pneumococcal pneumonia. Eur Respir J 2012 [In press].
16. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012;34:107-25.
17. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008;83:536-45. (Pubitemid 351966862)
18. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002;196:561-4. (Pubitemid 35024435)
19. Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989;264:10351-3. (Pubitemid 19161593)
20. Conway EM, Van de WM, Pollefeyt S, Jurk K, Van Aken H, De Vriese A et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002;196:565-77.
21. Morser J. Thrombomodulin links coagulation to inflammation and immunity. Curr Drug Targets 2012;13:421-31.
22. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-5. (Pubitemid 16141974)
23. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16345: 408-416.
24. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008;34:459-68.
25. Tsuruta K, Yamada Y, Serada M, Tanigawara Y. Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects. J Clin Pharmacol 2011;51:1276-85.
26. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41. (Pubitemid 44921064)
27. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011;35:349-54.
28. Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y et al. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 2012;72:1150-7.
29. Hayakawa M, Yamamoto H, Honma T, Mukai N, Higashiyama A, Sugano M et al. Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment. Shock 2012;37:569-73.